Skip to main
DTIL

Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision Biosciences (DTIL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precision BioSciences is a clinical stage gene editing company with a promising outlook due to the potential of its innovative and differentiated ARCUS gene editing platform. Its lead programs, PBGENE-DMD and PBGENE-HBV, have shown strong preclinical and early clinical data, with first-patient dosing expected for PBGENE-DMD in the near-term. The company's focus on curing diseases at the genetic level, rather than just managing symptoms, sets it apart from competitors. However, risks remain, including clinical development and commercialization risk, as well as potential dilution from future equity raises. The company's management is working to align with investigators on its NUC-withdrawal framework for HBV, which is seen as a crucial catalyst for the stock. Overall, the company's innovative approach and promising data make it an attractive investment opportunity, with a price target of $60.

Bears say

Precision BioSciences is facing several challenges, including the optimization of dosing and schedule of its clinical stage gene editing therapies, as well as the potential burden of administration for patients. Additionally, while the company's commercial prospects are promising, there are questions surrounding last-line vs. broad adoption. However, the company's recent clinical data showing successful elimination of cccDNA in patients with chronic hepatitis B and the potential for a finite cure strategy support its long-term potential. Despite these positive developments, the stock is facing headwinds and is best avoided for now.

Precision Biosciences (DTIL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precision Biosciences (DTIL) Forecast

Analysts have given Precision Biosciences (DTIL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Precision Biosciences (DTIL) has a Strong Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precision Biosciences (DTIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.